Macronutrient/alcohol |
|
|
|
|
Total sugar intake† |
ukb-b-17079; 100008: Output from GWAS pipeline
using Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
64 979 |
Elsworth, 201811
|
Carbohydrate intake† |
ukb-b-7244; 100005: Output from GWAS pipeline
using Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
64 979 |
Elsworth, 201811
|
Protein intake† |
ukb-b-12043; 100003: Output from GWAS pipeline using
Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
64 979 |
Elsworth, 201811
|
Fat intake† |
ukb-b-12379: 100004: Output from GWAS pipeline using
Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
64 979 |
Elsworth, 201811
|
Alcohol intake† |
ukb-b-5359; 100022: Output from GWAS pipeline using
Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
64 979 |
Elsworth, 201811
|
Anthropometric trait |
|
|
|
|
Body mass index |
NA |
GIANT+UKBB |
708 052 |
Pulit,
201912
|
Waist circumference |
ukb-b-9405; 48: Output from GWAS pipeline using
Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
462 166 |
Elsworth, 201811
|
Hip circumference |
ukb-b-15590; 49: Output from GWAS pipeline using
Phesant derived variables from UKBiobank (MRC-IEU) |
UKBB |
462 117 |
Elsworth, 201811
|
Waist-to-hip ratio |
NA |
GIANT+UKBB |
619 363 |
Pulit,
201912
|
Body fat percentage |
ukb-b-8909; 23099: Output from GWAS pipeline using
Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
454 633 |
Elsworth, 201811
|
Cardiometabolic trait |
|
|
|
|
Fasting glucose |
ebi-a-GCST005186 |
MAGIC |
58 074 |
Manning,
201213
|
Fasting insulin |
ebi-a-GCST005185 |
MAGIC |
51 750 |
Manning,
201213
|
Triglycerides |
ieu-a-302 |
GLGC |
177 861 |
Willer,
201314
|
LDL cholesterol |
ieu-a-300 |
GLGC |
173 082 |
Willer,
201314
|
HDL cholesterol |
ieu-a-299 |
GLGC |
187 167 |
Willer,
201314
|
Systolic blood pressure |
ukb-b-20175; 4080: Output from GWAS pipeline
using Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
436 419 |
Elsworth, 201811
|
Diastolic blood pressure |
ukb-b-7992; 4079: Output from GWAS pipeline
using Phesant derived variables from UKBB (MRC-IEU) |
UKBB |
436 424 |
Elsworth, 201811
|
C-reactive protein level |
NA |
UKBB |
343 524 |
Neale,
2018 |
Liver enzyme/metabolite |
|
|
|
|
Alanine aminotransferase |
ukb-d-30620_irnt |
UKBB |
NA |
Neale,
201811
|
Alkaline phosphatase |
ukb-d-30610_irnt |
UKBB |
NA |
Neale,
201811
|
Aspartate aminotransferase |
ukb-d-30650_irnt |
UKBB |
NA |
Neale,
201811
|
Gamma glutamyltransferase |
ukb-d-30730_irnt |
UKBB |
NA |
Neale,
201811
|
Direct bilirubin |
ukb-d-30660_irnt |
UKBB |
NA |
Neale,
201811
|
Total bilirubin |
ukb-d-30840_irnt |
UKBB |
NA |
Neale,
201811
|
Cardiometabolic disease |
|
|
|
|
Coronary artery disease |
ebi-a-GCST005195 |
CARDIoGRAMplusC4D and UKBB |
122 773/424 528 |
van der Harst,
201715
|
Coronary artery disease |
I9_IHD |
FinnGen consortium |
25 366/151 533 |
NA16
|
Heart failure |
NA |
HERMES (incl. UKBB) |
41 734/930 298 |
Shah,
202017
|
Heart failure |
I9_HEARTFAIL |
FinnGen consortium |
9576/159 286 |
NA16
|
Atrial fibrillation |
ebi-a-GCST006414 |
NA (incl. UKBB) |
60 620/970 216 |
Nielsen, 201818
|
Atrial fibrillation |
I9_AF |
FinnGen consortium |
17 325/97 214 |
NA16
|
Ischemic stroke |
NA |
MEGASTROKE |
34 217/406 111 |
Malik,
201819
|
Ischemic stroke |
ukb-d-I9_STR_EXH |
UKBB |
3314/357 880 |
Neale,
201811
|
Ischemic stroke |
I9_STR_EXH |
FinnGen consortium |
8046/164 286 |
NA16
|
Venous thromboembolism |
ukb-d-I9_VTE |
UKBB |
4620/356 574 |
Neale,
201711
|
Venous thromboembolism |
I9_VTE |
FinnGen consortium |
6913/169 986 |
NA16
|
Type 2 diabetes |
NA |
DIAMANTE (incl. UKBB) |
74 124/824 006 |
Mahajan,
201820
|
Type 2 diabetes |
E4_DM2_STRICT (exclude type 1 diabetes) |
FinnGen
consortium |
22 338/148 190 |
NA16
|
Other outcomes |
|
|
|
|
Alzheimer’s disease |
NA |
Consortia‡ and UKBB |
71 880/383 378§ |
Jansen, 201921
|
Parental lifespan |
NA |
LifeGene and UKBB |
639 143 |
Timmers,
201922
|